(Q46423677)

English

Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment

scientific article published in March 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

chronic hepatitis B

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hiromitsu Kumada

14

object named as

Hiromitsu Kumada

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

Fumitaka Suzuki

2

object named as

Fumitaka Suzuki

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

13

object named as

Kenji Ikeda

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

Masahiro Kobayashi

10

object named as

Masahiro Kobayashi

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

Yoshiyuki Suzuki

6

object named as

Yoshiyuki Suzuki

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

1

object named as

Norio Akuta

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

12

object named as

Yasuji Arase

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

7

object named as

Hitomi Sezaki

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

11

object named as

Satoshi Saitoh

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

Mariko Kobayashi

3

object named as

Mariko Kobayashi

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

9

object named as

Takashi Someya

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

author name string

Marie Matsuda

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

Junko Sato

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

Tetsuya Hosaka

8

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 March 2005

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

48

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

2-3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

174-182

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Classification of chronic hepatitis: diagnosis, grading and staging

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Avoiding false positives with PCR

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Dynamics of hepatitis B virus infection in vivo

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Treatment of chronic hepatitis B: case selection and duration of therapy

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment.

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Virological and biochemical relapse according to YMDD motif mutant type during long‐term lamivudine monotherapy

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Clinical relevance of hepatitis B viral mutations

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Persistence of YMDD variants after withdrawal of Lamivudine.

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Protein kinase C-dependent distribution of the multidrug resistance protein 2 from the canalicular to the basolateral membrane in human HepG2 cells

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

1 reference

https://api.crossref.org/works/10.1159%2F000081746

21 January 2018

Identifiers

10.1159/000081746

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15812192

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46423677&oldid=2110559467"